MAP2K7 and cancer: In KRAS mutant cancers, the phosphatidylinositol 3-kinase (PI3K) genotype influences the patient’s sensitivity to MEK inhibitors.8PIK3CA mutations in various cancer cells correlate with resistance to MEK inhibitors, and cells transduced with PI3K mutant are resistant to MEK inhibition.